Simcere Pharmaceutical Group Ltd. reported its unaudited financial results for the six months ended June 30, 2025. The Group recorded revenue of RMB3,585 million, an increase of 15.1% compared to RMB3,114 million for the same period in 2024. Revenue from the innovative pharmaceutical business reached RMB2,776 million, accounting for 77.4% of total revenue and representing a 26.0% increase from RMB2,203 million in the prior-year period. Profit attributable to equity shareholders of the Company was RMB604 million, a rise of RMB147 million or 32.2% from RMB457 million a year earlier. Adjusted profit attributable to equity shareholders stood at RMB651 million, up RMB113 million or 21.1% from RMB538 million in the corresponding period of 2024. Simcere Pharmaceutical Group stated that it continues to focus on R&D-driven innovation, with business operations primarily targeting neuroscience, oncology, autoimmune, and anti-infection therapeutic areas. No specific outlook or guidance for future periods was included in the released report.